Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Plasma cell 3Breast 3Tumor-Agnostic 2Other hematologic neoplasm 2Gynecologic 2Genitourinary 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Malignant Solid Neoplasm 1

Interventions

pembrolizumab 27Pemetrexed 10Nivolumab 10Cyclophosphamide 10Carboplatin 10atezolizumab 8Specimen Handling 8Cisplatin 8Ipilimumab 6Biopsy 6fludarabine 5Injections 5tislelizumab 4spartalizumab 4Vincristine 4Radiotherapy 4Proton Therapy 4Platinum 4Paclitaxel 4Drug Therapy 4Docetaxel 4Bevacizumab 41,2-diaminocyclohexaneplatinum II citrate 4sintilimab 3durvalumab 3Trastuzumab 3Etoposide 3Cetuximab 3zimberelimab 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × copanlisib × Other solid neoplasm × Clear all
NCT06360588 2026-05-28

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡